Previous Close | 1.1500 |
Open | 1.1600 |
Bid | 1.1400 x 1000 |
Ask | 1.1500 x 2200 |
Day's Range | 1.0600 - 1.1600 |
52 Week Range | 1.0600 - 7.6800 |
Volume | |
Avg. Volume | 476,060 |
Market Cap | 27.217M |
Beta (5Y Monthly) | 0.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -10.1600 |
Earnings Date | Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for BIOR
It’s the final day of trading this week and we’re starting it with a breakdown of the biggest pre-market stock movers on Friday morning! Moving stocks this morning are updates from the U.S. Food and Drug Administration (FDA), public share offerings and more. Let’s get into that news below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biggest Pre-Market Stock Movers: 10 Top Gainers Green Giant (NASDAQ:GGE) stock is rocketing more than 108% after revealing details of its 2023 Equi
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative col
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2023 Earnings Call Transcript November 13, 2023 Biora Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-4.89 EPS, expectations were $-0.93. Operator: Greetings and welcome to the Biora Therapeutics Third Quarter 2023 earnings call. At this time, all participants are in a listen only mode. A brief question-and-answer session […]